



Sen. Michael Connelly

**Filed: 3/12/2015**

09900SB0029sam001

LRB099 02785 JLK 31991 a

1 AMENDMENT TO SENATE BILL 29

2 AMENDMENT NO. \_\_\_\_\_. Amend Senate Bill 29 as follows:

3 on page 4, above line 9, by inserting the following:

4 "Section 80. The Nursing Home Care Act is amended by  
5 changing Section 2-104 as follows:

6 (210 ILCS 45/2-104) (from Ch. 111 1/2, par. 4152-104)

7 Sec. 2-104. (a) A resident shall be permitted to retain the  
8 services of his own personal physician at his own expense or  
9 under an individual or group plan of health insurance, or under  
10 any public or private assistance program providing such  
11 coverage. However, the facility is not liable for the  
12 negligence of any such personal physician. Every resident shall  
13 be permitted to obtain from his own physician or the physician  
14 attached to the facility complete and current information  
15 concerning his medical diagnosis, treatment and prognosis in

1 terms and language the resident can reasonably be expected to  
2 understand. Every resident shall be permitted to participate in  
3 the planning of his total care and medical treatment to the  
4 extent that his condition permits. No resident shall be  
5 subjected to experimental research or treatment without first  
6 obtaining his informed, written consent. The conduct of any  
7 experimental research or treatment shall be authorized and  
8 monitored by an institutional review board appointed by the  
9 Director. The membership, operating procedures and review  
10 criteria for the institutional review board shall be prescribed  
11 under rules and regulations of the Department and shall comply  
12 with the requirements for institutional review boards  
13 established by the federal Food and Drug Administration. No  
14 person who has received compensation in the prior 3 years from  
15 an entity that manufactures, distributes, or sells  
16 pharmaceuticals, biologics, or medical devices may serve on the  
17 institutional review board.

18 The institutional review board may approve only research or  
19 treatment that meets the standards of the federal Food and Drug  
20 Administration with respect to (i) the protection of human  
21 subjects and (ii) financial disclosure by clinical  
22 investigators. The Office of State Long Term Care Ombudsman and  
23 the State Protection and Advocacy organization shall be given  
24 an opportunity to comment on any request for approval before  
25 the board makes a decision. Those entities shall not be  
26 provided information that would allow a potential human subject

1 to be individually identified, unless the board asks the  
2 Ombudsman for help in securing information from or about the  
3 resident. The board shall require frequent reporting of the  
4 progress of the approved research or treatment and its impact  
5 on residents, including immediate reporting of any adverse  
6 impact to the resident, the resident's representative, the  
7 Office of the State Long Term Care Ombudsman, and the State  
8 Protection and Advocacy organization. The board may not approve  
9 any retrospective study of the records of any resident about  
10 the safety or efficacy of any care or treatment if the resident  
11 was under the care of the proposed researcher or a business  
12 associate when the care or treatment was given, unless the  
13 study is under the control of a researcher without any business  
14 relationship to any person or entity who could benefit from the  
15 findings of the study.

16 No facility shall permit experimental research or  
17 treatment to be conducted on a resident, or give access to any  
18 person or person's records for a retrospective study about the  
19 safety or efficacy of any care or treatment, without the prior  
20 written approval of the institutional review board. No nursing  
21 home administrator, or person licensed by the State to provide  
22 medical care or treatment to any person, may assist or  
23 participate in any experimental research on or treatment of a  
24 resident, including a retrospective study, that does not have  
25 the prior written approval of the board. Such conduct shall be  
26 grounds for professional discipline by the Department of

1 Financial and Professional Regulation.

2 The institutional review board may exempt from ongoing  
3 review research or treatment initiated on a resident before the  
4 individual's admission to a facility and for which the board  
5 determines there is adequate ongoing oversight by another  
6 institutional review board. Nothing in this Section shall  
7 prevent a facility, any facility employee, or any other person  
8 from assisting or participating in any experimental research on  
9 or treatment of a resident, if the research or treatment began  
10 before the person's admission to a facility, until the board  
11 has reviewed the research or treatment and decided to grant or  
12 deny approval or to exempt the research or treatment from  
13 ongoing review.

14 The institutional review board requirements of this  
15 subsection (a) do not apply to investigational drugs,  
16 biological products, or devices used by a resident with a  
17 terminal illness as set forth in the Right to Try Act.

18 (b) All medical treatment and procedures shall be  
19 administered as ordered by a physician. All new physician  
20 orders shall be reviewed by the facility's director of nursing  
21 or charge nurse designee within 24 hours after such orders have  
22 been issued to assure facility compliance with such orders.

23 All physician's orders and plans of treatment shall have  
24 the authentication of the physician. For the purposes of this  
25 subsection (b), "authentication" means an original written  
26 signature or an electronic signature system that allows for the

1 verification of a signer's credentials. A stamp signature, with  
2 or without initials, is not sufficient.

3 According to rules adopted by the Department, every woman  
4 resident of child-bearing age shall receive routine  
5 obstetrical and gynecological evaluations as well as necessary  
6 prenatal care.

7 (c) Every resident shall be permitted to refuse medical  
8 treatment and to know the consequences of such action, unless  
9 such refusal would be harmful to the health and safety of  
10 others and such harm is documented by a physician in the  
11 resident's clinical record. The resident's refusal shall free  
12 the facility from the obligation to provide the treatment.

13 (d) Every resident, resident's guardian, or parent if the  
14 resident is a minor shall be permitted to inspect and copy all  
15 his clinical and other records concerning his care and  
16 maintenance kept by the facility or by his physician. The  
17 facility may charge a reasonable fee for duplication of a  
18 record.

19 (Source: P.A. 96-1372, eff. 7-29-10; 97-179, eff. 1-1-12.);  
20 and

21 on page 4, line 9, by replacing "Section 30." with "Section  
22 90.".